EGFR and non-small cell lung carcinoma: In the FLAURA trial, which evaluated first-line osimertinib in EGFR-mutated NSCLC patients [58], and the AURA3 trial, which evaluated osimertinib in patients with acquired T790M resistance [123], paired plasma samples were collected at baseline and at progression.